Combinations of mRNAs encoding immune modulating polypeptides and uses thereof

Patent metadata

Field	Value
Publication number	US-10322091-B2
Application number	US-201816219418-A
Country	US
Kind code	B2
Filing date	Dec 13, 2018
Priority date	May 18, 2016
Publication date	Jun 18, 2019
Grant date	Jun 18, 2019

Abstract

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

First claim

The invention claimed is:

1. A lipid nanoparticle comprising:
(i) a first mRNA comprising an open reading frame (ORF) encoding a human IL-23 polypeptide;
(ii) a second mRNA comprising an ORF encoding a human IL-36 gamma polypeptide; and
(iii) a third mRNA comprising an ORF encoding a human OX40L polypeptide.

2. The lipid nanoparticle of claim 1 , wherein the IL-23 polypeptide comprises an IL-12p40 polypeptide operably linked, with or without a linker, to an IL-23p19 polypeptide.

3. The lipid nanoparticle of claim 1 , wherein the IL-23 polypeptide comprises an IL-12p40 polypeptide operably linked via a linker to an IL-23p19 polypeptide.

4. The lipid nanoparticle of claim 3 , wherein the linker is a Gly/Ser linker.

5. The lipid nanoparticle of claim 2 , wherein the IL-12p40 polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence as set forth in SEQ ID NO: 1 and the amino acid sequence as set forth in SEQ ID NO:3, and wherein the IL-23p19 polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence as set forth in SEQ ID NO: 4 and the amino acid sequence as set forth in SEQ ID NO: 5.

6. The lipid nanoparticle of claim 4 , wherein the IL-23 polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 140.

7. The lipid nanoparticle of claim 1 , wherein the IL-36 gamma polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence as set forth in SEQ ID NO: 10, the amino acid sequence as set forth in SEQ ID NO: 12, and the amino acid sequence as set forth in SEQ ID NO: 16.

8. The lipid nanoparticle of claim 1 , wherein the OX40L polypeptide comprises an amino acid sequence selected from the group consisting of the amino acid sequence as set forth in SEQ ID NO: 2, and the amino acid sequence as set forth in SEQ ID NO: 21.

9. The lipid nanoparticle of claim 1 , wherein each of the first, second, and third mRNAs comprise a 5′cap, a 5′untranslated region (UTR), a 3′UTR and a polyA tail.

10. The lipid nanoparticle of claim 9 , wherein the 3′UTR comprises a miR-122 binding site.

11. The lipid nanoparticle of claim 1 , wherein the first, second, and third mRNAs are formulated in the lipid nanoparticle at a mass ratio of OX40L:IL-23:IL-36 gamma of 1:1:2.

12. The lipid nanoparticle of claim 1 , comprising an ionizable amino lipid comprising a compound having the formula:

13. The lipid nanoparticle of claim 12 , further comprising a phospholipid, a sterol, and a PEG-modified lipid.

14. A lipid nanoparticle comprising:
(i) a first mRNA comprising an ORF encoding a human IL-23 polypeptide;
(ii) a second mRNA comprising an ORF encoding a human IL-36 gamma polypeptide; and
(iii) a third mRNA comprising an ORF encoding a human OX40L polypeptide,
wherein each of the first, second, and third mRNAs are fully modified with chemically-modified uridines.

15. The lipid nanoparticle of claim 14 , wherein each of the first, second, and third mRNAs are fully modified with N1-methylpseudouridine.

16. The lipid nanoparticle of claim 14 , wherein the first, second, and third mRNAs are formulated in the lipid nanoparticle at a mass ratio of OX40L:IL-23:IL-36 gamma of 1:1:2.

17. The lipid nanoparticle of claim 14 , comprising an ionizable amino lipid comprising a compound having the formula:

18. The lipid nanoparticle of claim 17 , further comprising a phospholipid, a sterol, and a PEG-modified lipid.

19. A lipid nanoparticle comprising:
(i) a first mRNA comprising an ORF encoding a human IL-23 polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 140;
(ii) a second mRNA comprising an ORF encoding a human IL-36 gamma polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 16; and
(iii) a third mRNA comprising an ORF encoding a human OX40L polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 21.

20. The lipid nanoparticle of claim 19 , wherein each of the first, second, and third mRNAs comprise a 5′cap, a 5′UTR, a 3′UTR and a polyA tail.

21. The lipid nanoparticle of claim 20 , wherein the 3′UTR comprises a miR-122 binding site.

22. The lipid nanoparticle of claim 19 , wherein the first, second, and third mRNAs are formulated in the lipid nanoparticle at a mass ratio of OX40L:IL-23:IL-36 gamma of 1:1:2.

23. The lipid nanoparticle of claim 19 , comprising an ionizable amino lipid comprising a compound having the formula:

24. The lipid nanoparticle of claim 23 , further comprising a phospholipid, a sterol, and a PEG-modified lipid.

25. A lipid nanoparticle comprising:
(i) a first mRNA comprising an ORF encoding a human IL-23 polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 140;
(ii) a second mRNA comprising an ORF encoding a human IL-36 gamma polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 16; and
(iii) a third mRNA comprising an ORF encoding a human OX40L polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 21,
wherein each of the first, second, and third mRNAs are fully modified with N1-methylpseudouridines.

26. The lipid nanoparticle of claim 25 , wherein each of the first, second, and third mRNAs comprise a 5′cap, a 5′ untranslated region (UTR), a 3′UTR and a polyA tail.

27. The lipid nanoparticle of claim 26 , wherein the 3′UTR comprises a miR-122 binding site.

28. The lipid nanoparticle of claim 25 , wherein the first, second, and third mRNAs are formulated in the lipid nanoparticle at a mass ratio of OX40L:IL-23:IL-36 gamma of 1:1:2.

29. The lipid nanoparticle of claim 25 , comprising an ionizable amino lipid comprising a compound having the formula:

30. The lipid nanoparticle of claim 29 , further comprising a phospholipid, a sterol, and a PEG-modified lipid.

Assignees

• Modernatx Inc

Inventors

• Frederick Joshua
• Bai Ailin
• Presnyak Vladimir
• Hoge Stephen
• Benenato Kerry
• Mcfadyen Iain
• Kumarasinghe Ellalahewage Sathyajith
• Hewitt Susannah

Classifications

• A61K9/1272

  comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title

• C07K14/5446

  IL-16 · CPC title

• A61K38/20 Primary

  Interleukins [IL] · CPC title

• A61K2039/51

  comprising whole cells, viruses or DNA/RNA · CPC title

• C07K14/545

  IL-1 · CPC title